8 Best Gene-Editing Stocks to Buy

3. Moderna, Inc. (NASDAQ:MRNA) 

Number of Hedge Fund Holders: 44 

The third stock on our list of the best gene-editing stocks to buy is Moderna, Inc. (NASDAQ:MRNA). It is a biotechnology company focused on developing mRNA-based therapeutics and vaccines for a variety of diseases, including COVID-19, cancer, and cardiovascular conditions. What sets the company apart in the gene-editing field is its innovative use of mRNA technology combined with gene-editing tools for in vivo therapies, which directly alter genes within a patient’s body. This approach aims to overcome challenges faced by traditional gene therapies. The corporation’s rapid development of the COVID-19 vaccine highlights its ability to quickly create mRNA-based treatments, positioning the company as a leader in addressing emerging health threats and unmet medical needs.

Moderna, Inc. (NASDAQ:MRNA)’s target market spans a wide range of areas, including infectious diseases, cancer, and rare genetic disorders. After the success of its COVID-19 vaccine, Spikevax, the company is expanding its pipeline to address other critical areas, such as respiratory vaccines for COVID-19, influenza, and RSV, as well as vaccines for rare diseases like CMV and EBV. The corporation is also working on cancer immunotherapies, particularly for melanoma.

For 2024, Moderna, Inc. (NASDAQ:MRNA) recorded a revenue of $3.2 billion, a 53% decrease from the previous year, mainly due to lower sales of Spikevax. The company reported a net loss of $3.6 billion for the year, an improvement from the $4.7 billion loss in 2023. This drop in revenue was expected, as the demand for COVID-19 vaccines has slowed. However, the business’s efforts to cut costs—by reducing operating expenses and optimizing operations—helped mitigate the impact on its profitability.

Moderna, Inc. (NASDAQ:MRNA) ended the year with $9.5 billion in cash, up slightly from the previous quarter. Despite the revenue decline, the company’s cost-saving measures, reduced R&D expenses, and a focus on strategic investments in its mRNA-based pipeline position it for continued growth beyond the pandemic era.